Editas Medicine, Inc.

EDIT

Editas Medicine, Inc.

EDIT

Insider Sentiment (TTM):

Last Purchase:2024-05-13Last Sale:2026-06-03Shares Purchased (TTM):0Shares Sold (TTM):36,729

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:47,656,436Shares Outstanding:97,879,343Institutional Ownership Pct.:48.69%

Earnings Market Reaction:

Filing Date:2026-08-05Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	182	124	147	166	139	139	132	96	64	69	124	83
Marketable Securities Current	-	-	0	0	40	82	138	169	215	227	199	267
Receivables Net Current	3	3	15	8	1	1	16	0	0	0	10	2
Prepaid Expense And Other Assets Current	4	2	2	3	4	3	3	6	7	9	8	7
Assets Current	218	128	164	177	183	225	289	271	286	306	341	359
Property Plant And Equipment Net	3	3	4	4	5	8	14	15	14	13	12	12
Marketable Securities Noncurrent	-	-	-	-	-	-	0	0	39	81	104	97
Operating Lease Right Of Use Asset	14	15	16	18	19	26	33	36	37	31	34	32
Other Assets Noncurrent	3	3	3	3	4	4	5	5	8	9	9	6
Assets	237	149	187	202	211	264	342	328	385	440	499	505
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	5	4	3	3	7	5	5	12	14	8	8	10
Accrued Liabilities Current	17	21	33	48	48	47	46	29	28	31	35	30
Long Term Debt Current	8	8	5	5	5	5	5	-	-	-	0	-
Contract With Customer Liability Current	-	-	0	0	0	2	6	15	15	15	8	8
Operating Lease Liability Current	7	7	6	6	6	13	15	16	18	12	12	10
Liabilities Current	68	40	46	62	66	73	77	72	74	66	63	59
Operating Lease Liability Noncurrent	9	11	12	14	15	18	20	22	21	22	24	25
Long Term Debt Noncurrent	48	47	54	54	52	50	52	-	-	-	0	-
Contract With Customer Liability Noncurrent	4	45	45	54	54	54	54	54	54	54	61	61
Other Liabilities Noncurrent	2	3	3	5	5	6	3	3	4	3	2	-
Liabilities	132	145	159	188	191	201	207	152	153	146	150	144
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	1,777	1,658	1,656	1,636	1,617	1,607	1,602	1,598	1,593	1,588	1,580	1,574
Accumulated Other Comprehensive Income Loss Net Of…	-0	0	0	0	0	0	0	1	-0	-0	0	-1
Retained Earnings Accumulated Deficit	-1,672	-1,653	-1,629	-1,623	-1,598	-1,545	-1,468	-1,423	-1,361	-1,293	-1,231	-1,212
Stockholders Equity	105	4	27	13	19	62	134	176	232	294	349	360
Liabilities And Stockholders Equity	237	149	187	202	211	264	342	328	385	440	499	505
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	390	390	390	390	390	195	195	195	195	195	195	195
Common Stock Shares Issued	154	98	98	93	87	84	83	83	82	82	82	82
Shares Outstanding	98	98	98	93	87	84	83	83	82	82	82	82

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	13.82%	-6.25%	-14.47%	-	-	-	-	-	-	-	-	-
2025	24.03%	66.88%	58.44%	20.52%	71.18%	34.50%	-3.97%	-18.65%	-21.03%	15.09%	25.00%	49.14%
2024	3.28%	-7.25%	12.21%	-9.00%	-15.33%	-22.63%	-22.22%	-57.99%	-52.08%	-39.02%	-24.88%	-24.39%
2023	-	-	-	-	-	-	27.32%	30.32%	-2.65%	-32.52%	-50.41%	-49.23%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	3.19	3.22	3.54	2.86	2.77	3.08	3.75	3.75	3.85	4.60	5.39	6.12
Quick Ratio	3.13	3.17	3.50	2.81	2.72	3.03	3.71	3.67	3.76	4.46	5.27	6.01
Working Capital	149.63M	88.29M	117.65M	115.12M	116.86M	151.73M	212.09M	198.79M	212.05M	239.07M	277.61M	300.00M
Leverage & Debt
Debt to Equity	1.25	32.88	5.84	14.00	9.97	3.22	1.54	0.87	0.66	0.50	0.43	0.40
Interest Coverage TTM	-15.18	-18.28	-22.54	-22.53	-37.34	-59.08	-114.68	-	-	-	-	-
Debt Ratio	0.56	0.97	0.85	0.93	0.91	0.76	0.61	0.46	0.40	0.33	0.30	0.29
Efficiency & Turnover
Asset Turnover TTM	0.21	0.19	0.15	0.18	0.13	0.10	0.08	0.15	0.14	0.15	0.15	0.05
Days Sales Outstanding TTM	12.86	14.63	141.61	32.48	3.90	3.84	149.40	7.53	6.89	1.28	35.82	18.85
Receivables Turnover TTM	28.38	24.95	2.58	11.24	93.51	94.93	2.44	48.48	52.99	285.04	10.19	19.36
Per Share Metrics
Diluted EPS TTM	-0.62	-1.11	-1.80	-2.22	-2.81	-3.02	-2.88	-2.55	-2.35	-2.03	-2.02	-2.39
Free Cash Flow Per Share TTM	-1.01	-1.44	-1.87	-2.01	-2.43	-2.59	-2.66	-2.32	-2.08	-1.84	-1.80	-1.91
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-161.39%	-281.32%	-394.89%	-428.70%	-616.84%	-726.41%	-777.22%	-370.03%	-317.78%	-266.85%	-216.56%	-847.85%
Net Profit Margin TTM	-157.32%	-281.59%	-395.01%	-430.83%	-608.86%	-701.04%	-733.72%	-340.96%	-288.59%	-239.36%	-196.13%	-792.67%
Growth Metrics
Net Revenue Growth (1Y)	20.83%	7.97%	25.39%	-24.89%	-41.97%	-48.37%	-58.64%	150.94%	247.02%	204.52%	296.32%	-4.03%
Net Income Growth (1Y)	-68.78%	-56.63%	-32.49%	-5.10%	22.44%	51.22%	54.74%	7.94%	-6.00%	-24.12%	-30.49%	-3.01%
EPS Growth (1Y)	-77.91%	-63.20%	-37.36%	-13.11%	19.39%	49.19%	42.77%	6.84%	-18.48%	-36.18%	-37.17%	-18.35%
Valuation Metrics
P/E TTM	-5.23	-2.22	-1.14	-1.56	-0.78	-0.38	-0.44	-1.34	-1.99	-3.66	-5.02	-3.26
P/B TTM	3.67	54.85	6.67	23.24	9.68	1.54	0.78	1.60	1.66	2.07	2.20	1.77
P/S TTM	8.22	6.25	4.49	6.74	4.77	2.69	3.24	4.55	5.73	8.76	9.85	25.88
Market Cap	386.51M	241.76M	181.93M	312.61M	185.71M	96.34M	104.57M	281.27M	384.39M	607.99M	769.53M	636.86M
Enterprise Value	257.77M	170.12M	91.22M	206.03M	99.96M	8.35M	26.59M	181.57M	316.07M	534.88M	642.00M	554.32M
Calculated Values
Free Cash Flow TTM	-120.55M	-141.09M	-165.85M	-180.70M	-204.94M	-215.28M	-219.11M	-191.36M	-171.54M	-151.03M	-136.90M	-156.25M
Net Debt	-128.75M	-71.64M	-90.71M	-106.58M	-85.75M	-87.99M	-77.98M	-99.71M	-68.32M	-73.10M	-127.53M	-82.54M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-03Sale

Owner: Burkly, Linda

Title: EVP, CHIEF SCIENTIFIC OFFICER

Shares: 731

Price/Share: $2.70

Value: $1,973.70

Shares Owned: 67,297

Relationship: Officer

Ownership: Direct

2026-06-03Sale

Owner: O'Neill, Gilmore Neil

Title: CEO

Shares: 15,380

Price/Share: $2.70

Value: $41,526.00

Shares Owned: 248,313

Relationship: Director,Officer

Ownership: Direct

2026-06-03Sale

Owner: Parison, Amy

Title: SVP, Chief Financial Officer

Shares: 464

Price/Share: $2.70

Value: $1,252.80

Shares Owned: 14,970

Relationship: Officer

Ownership: Direct

2026-03-03Sale

Owner: Parison, Amy

Title: SVP, Chief Financial Officer

Shares: 474

Price/Share: $2.02

Value: $957.48

Shares Owned: 15,434

Relationship: Officer

Ownership: Direct

2026-03-03Sale

Owner: O'Neill, Gilmore Neil

Title: CEO

Shares: 5,394

Price/Share: $2.02

Value: $10,895.88

Shares Owned: 263,693

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-03	Burkly, Linda	Officer	EVP, CHIEF SCIENTIFIC OFFICER	Direct	Sale	731	2.70	$1,973.70	67,297	4
2026-06-03	O'Neill, Gilmore Neil	Director,Officer	CEO	Direct	Sale	15,380	2.70	$41,526.00	248,313	4
2026-06-03	Parison, Amy	Officer	SVP, Chief Financial Officer	Direct	Sale	464	2.70	$1,252.80	14,970	4
2026-03-03	Parison, Amy	Officer	SVP, Chief Financial Officer	Direct	Sale	474	2.02	$957.48	15,434	4
2026-03-03	O'Neill, Gilmore Neil	Director,Officer	CEO	Direct	Sale	5,394	2.02	$10,895.88	263,693	4
2026-03-03	Burkly, Linda	Officer	EVP, CHIEF SCIENTIFIC OFFICER	Direct	Sale	749	2.02	$1,512.98	68,028	4
2025-12-03	O'Neill, Gilmore Neil	Director,Officer	CEO	Direct	Sale	5,603	2.15	$12,046.45	269,087	4
2025-12-03	Parison, Amy	Officer	SVP, Chief Financial Officer	Direct	Sale	461	2.15	$991.15	15,908	4
2025-12-03	Burkly, Linda	Officer	EVP, CHIEF SCIENTIFIC OFFICER	Direct	Sale	713	2.15	$1,532.95	68,777	4
2025-09-03	Parison, Amy	Officer	SVP, Chief Financial Officer	Direct	Sale	458	2.60	$1,190.80	16,369	4
2025-09-03	O'Neill, Gilmore Neil	Director,Officer	CEO	Direct	Sale	5,592	2.60	$14,539.20	274,690	4
2025-09-03	Burkly, Linda	Officer	EVP, CHIEF SCIENTIFIC OFFICER	Direct	Sale	710	2.60	$1,846.00	69,490	4
2025-08-07	Parison, Amy	Officer	SVP, Chief Financial Officer	Direct	Sale	679	2.58	$1,751.82	16,827	4
2025-07-31	Burkly, Linda	Officer	EVP, CHIEF SCIENTIFIC OFFICER	Direct	Sale	5,121	2.49	$12,751.29	64,398	4
2025-06-03	Parison, Amy	Officer	SVP, Chief Financial Officer	Direct	Sale	446	1.72	$767.12	17,506	4
2025-06-03	O'Neill, Gilmore Neil	Director,Officer	CEO	Direct	Sale	15,192	1.72	$26,130.24	280,282	4
2025-06-03	Burkly, Linda	Officer	EVP, CHIEF SCIENTIFIC OFFICER	Direct	Sale	726	1.72	$1,248.72	69,519	4
2025-03-04	Lucera, Erick	Officer	EVP, CHIEF FINANCIAL OFFICER	Direct	Sale	4,109	1.71	$7,026.39	112,720	4
2025-03-04	O'Neill, Gilmore Neil	Director,Officer	CEO	Direct	Sale	16,632	1.71	$28,440.72	295,474	4
2025-03-04	Burkly, Linda	Officer	EVP, CHIEF SCIENTIFIC OFFICER	Direct	Sale	2,891	1.71	$4,943.61	70,245	4
2024-12-03	Mei, Baisong	Officer	EVP, CHIEF MEDICAL OFFICER	Direct	Sale	541	2.08	$1,125.28	133,354	4
2024-12-03	O'Neill, Gilmore Neil	Director,Officer	CEO	Direct	Sale	1,618	2.08	$3,365.44	312,106	4
2024-09-04	O'Neill, Gilmore Neil	Director,Officer	CEO	Direct	Sale	1,555	3.42	$5,318.10	313,724	4
2024-09-04	Mei, Baisong	Officer	EVP, CHIEF MEDICAL OFFICER	Direct	Sale	518	3.42	$1,771.56	133,895	4
2024-07-25	Burkly, Linda	Officer	EVP, CHIEF SCIENTIFIC OFFICER	Direct	Sale	11,886	5.42	$64,422.12	73,136	4
2024-07-19	Mei, Baisong	Officer	EVP, CHIEF MEDICAL OFFICER	Direct	Sale	6,619	5.21	$34,484.99	134,413	4
2024-06-04	Mei, Baisong	Officer	EVP, CHIEF MEDICAL OFFICER	Direct	Sale	511	5.50	$2,810.50	141,032	4
2024-06-04	O'Neill, Gilmore Neil	Director,Officer	CEO	Direct	Sale	12,191	5.50	$67,050.50	315,279	4
2024-05-20	Lucera, Erick	Officer	EVP, CHIEF FINANCIAL OFFICER	Direct	Sale	22,337	5.61	$125,310.57	116,829	4
2024-05-13	Hopfield, Jessica	Director	-	Direct	Purchase	45,000	5.64	$253,800.00	67,700	4
2024-03-05	O'Neill, Gilmore Neil	Director,Officer	CEO	Direct	Sale	77,824	9.42	$733,102.08	327,470	4
2024-03-04	Mei, Baisong	Officer	SVP, CHIEF MEDICAL OFFICER	Direct	Sale	20,327	9.42	$191,480.34	141,543	4
2023-12-05	Eaton, Bruce	Officer	EVP, CBO AND CTO	Direct	Sale	103	10.90	$1,122.70	74,791	4
2023-11-14	Eaton, Bruce	Officer	EVP, CBO AND CTO	Direct	Sale	695	8.21	$5,705.95	74,894	4
2023-11-07	Eaton, Bruce	Officer	EVP, CBO AND CTO	Direct	Sale	139	8.40	$1,167.60	75,589	4
2023-09-06	Eaton, Bruce	Officer	EVP, CBO AND CTO	Direct	Sale	103	8.82	$908.46	75,728	4
2023-08-11	Eaton, Bruce	Officer	EVP, CBO AND CTO	Direct	Sale	702	8.59	$6,030.18	75,831	4
2023-08-08	Eaton, Bruce	Officer	EVP, CBO AND CTO	Direct	Sale	141	8.39	$1,182.99	76,533	4
2023-07-19	Mei, Baisong	Officer	SVP, CHIEF MEDICAL OFFICER	Direct	Sale	4,317	8.80	$37,989.60	72,055	4
2023-06-05	O'Neill, Gilmore Neil	Director,Officer	CEO	Direct	Sale	6,486	9.50	$61,617.00	130,169	4
2023-06-05	Eaton, Bruce	Officer	EVP, CBO AND CTO	Direct	Sale	105	9.50	$997.50	76,674	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

48.69%

Inst. Shares: 47,656,436

Shares Outstanding: 97,879,343

2025-12-31

54.13%

Inst. Shares: 48,039,293

Shares Outstanding: 88,745,908

2025-09-30

46.75%

Inst. Shares: 42,117,857

Shares Outstanding: 90,090,397

2025-06-30

47.40%

Inst. Shares: 40,011,145

Shares Outstanding: 84,412,200

2025-03-31

51.32%

Inst. Shares: 42,625,170

Shares Outstanding: 83,055,066

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	47,656,436	97,879,343	48.69%
2025-12-31	48,039,293	88,745,908	54.13%
2025-09-30	42,117,857	90,090,397	46.75%
2025-06-30	40,011,145	84,412,200	47.40%
2025-03-31	42,625,170	83,055,066	51.32%
2024-12-31	50,162,804	82,338,220	60.92%
2024-09-30	53,669,998	82,485,199	65.07%
2024-06-30	54,995,249	82,310,368	66.81%
2024-03-31	66,087,087	81,938,839	80.65%
2023-12-31	57,185,758	75,965,633	75.28%
2023-09-30	60,602,617	81,648,250	74.22%
2023-06-30	61,161,662	71,376,678	85.69%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Editas Medicine, Inc. (EDIT) — SEC Financial Statements & Analysis

Editas Medicine, Inc. (EDIT) is a biological products, (no diagnostic substances) company, incorporated in DE. Editas Medicine, Inc. trades on Nasdaq as: EDIT. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Editas Medicine, Inc. reported a 20.83% year-over-year revenue growth, a Debt-to-Equity ratio of 1.25x, a Price-to-Sales (P/S) ratio of 8.22x (TTM), a Price-to-Book (P/B) ratio of 3.67x (TTM), at a market cap of $386.51M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 20.83%
Debt To Equity: 1.25x
P/S TTM: 8.22x
P/B TTM: 3.67x
Market Cap: $386.51M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Editas Medicine, Inc. in?

Editas Medicine, Inc. (EDIT) operates in the Biological Products, (No Diagnostic Substances) industry.

What is EDIT's market cap?

Editas Medicine, Inc. (EDIT) has a market capitalization of $386.51M as of 2026-06-30.

What exchange does EDIT trade on?

Editas Medicine, Inc. (EDIT) trades on the Nasdaq.

Where is Editas Medicine, Inc. incorporated?

Editas Medicine, Inc. is incorporated in DE.